178 related articles for article (PubMed ID: 9062827)
1. Lipid-lowering effects of fluvastatin in renal transplant patients. A clinical observation.
Lal SM; Gupta N; Georgiev O; Ross G
Int J Artif Organs; 1997 Jan; 20(1):18-21. PubMed ID: 9062827
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
3. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
4. Effects of fluvastatin on hyperlipidemia after renal transplantation: influence of steroid therapy.
Austen JL; Shifrin FA; Bartucci MR; Knauss TC; Schulak JA; Hricik DE
Ann Pharmacother; 1996 Dec; 30(12):1386-9. PubMed ID: 8968448
[TBL] [Abstract][Full Text] [Related]
5. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
Goldberg RB; Roth D
Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Leitersdorf E; Muratti EN; Eliav O; Peters TK
Am J Cardiol; 1995 Jul; 76(2):84A-88A. PubMed ID: 7604807
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia.
Koizumi J; Haraki T; Yagi K; Inazu A; Kajinami K; Miyamoto S; Ueda K; Ohta M; Takegoshi T; Takeda M
Am J Cardiol; 1995 Jul; 76(2):47A-50A. PubMed ID: 7604797
[TBL] [Abstract][Full Text] [Related]
9. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin in severe hypercholesterolemia: analysis of a clinical trial database.
Peters TK
Am J Cardiol; 1995 Jul; 76(2):71A-75A. PubMed ID: 7604803
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of hypercholesterolemia of renal transplant allograft recipients with fluvastatin and gemfibrozil.
Vergoulas G; Miserlis G; Solonaki F; Imvrios G; Gakis D; Papanikolaou V; Papagiannis A; Visvardis G; Takoudas D; Antoniadis A
Transpl Int; 2000; 13 Suppl 1():S64-7. PubMed ID: 11111964
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin in hyperlipidemic patients treated with probucol.
Sasaki S; Nakagawa M; Nakata T; Endo N; Miyao K; Kitamura K; Fukuyama M; Kitani T; Yamada C
Cardiology; 1997; 88(2):160-5. PubMed ID: 9096917
[TBL] [Abstract][Full Text] [Related]
14. Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
Fanghänel G; Espinosa J; Olivares D; Sánchez L; Morales M; Martínez L; Macías G; Valdés E; Hernández G
Am J Cardiol; 1995 Jul; 76(2):57A-61A. PubMed ID: 7604800
[TBL] [Abstract][Full Text] [Related]
15. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. French Fluvastatin Study Group.
Jacotot B; Benghozi R; Pfister P; Holmes D
Am J Cardiol; 1995 Jul; 76(2):54A-56A. PubMed ID: 7604799
[TBL] [Abstract][Full Text] [Related]
17. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage.
Smit JW; Jansen GH; de Bruin TW; Erkelens DW
Am J Cardiol; 1995 Jul; 76(2):126A-128A. PubMed ID: 7604787
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients. The French-Dutch Fluvastatin Study Group.
Jacotot B; Banga JD; Pfister P; Mehra M
Br J Clin Pharmacol; 1994 Sep; 38(3):257-63. PubMed ID: 7826828
[TBL] [Abstract][Full Text] [Related]
19. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
20. Effects of fluvastatin and pravastatin on lipid profiles and thromboxane production in type IIa hypercholesterolemia.
Milani M; Cimminiello C; Merlo B; Lorena M; Arpaia G; Bonfardeci G
Am J Cardiol; 1995 Jul; 76(2):51A-53A. PubMed ID: 7604798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]